The performance of companies tied to Sildenafil's legacy presents a challenging investment landscape. While the initial success generated substantial profits , generic competition have significantly diminished market share . Investing in associated pharmaceutical businesses now requires a thorough assessment of proprietary safeguards, evolving pati